Tuoyi
(Toripalimab)Phase 3Monoclonal antibody
Toripalimab is a cancer immunotherapy drug that helps the body's immune system fight certain types of cancer by blocking a protein that cancer cells use to hide from the immune system.[1] Tuoyi is currently being investigated across 82 indications[3], with its most advanced program in Phase 3.[1]
Tuoyi is one of 1267 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 3.
82
Indications
313
Total Trials
110
Active Trials
1,266
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 82 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tuoyi
CCoherus Oncology, Inc.
Phase 3
Rilvegostomig
AstraZenecaPreclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Lapatinib Plus Capecitabine
GSKPreclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Trastuzuma
FFudan University
Preclinical
Atracurium Besylate
MMansoura University
Preclinical
Therapeutic Progesterone
EEmory University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Toripalimab13 trials
Toripalimab Combined With SBRT for NSCLC
Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06293690·40 enrolled
Show 10 more trials
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06221670·51 enrolled
Nasopharyngeal Carcinoma13 trials
Show 10 more trials
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Recruiting·—·Phase 3·NCT04376866·204 enrolled
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Not yet recruiting·—·Phase 2·NCT07136519·30 enrolled
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
Unknown status·—·Phase 2·NCT04992988·40 enrolled
Small Cell Lung Cancer9 trials
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruiting·—·Phase 2·NCT07376499·31 enrolled
Show 6 more trials
Breast Cancer9 trials
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07410234·110 enrolled
Show 6 more trials
Advanced Solid Tumors7 trials
Show 4 more trials
76 more indications
Esophageal Squamous Cell Carcinoma7 trials
Show 4 more trials
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07272291·48 enrolled
Patients With Advanced Solid Tumors6 trials
Show 3 more trials
Hepatocellular Carcinoma6 trials
Show 3 more trials
Esophageal Cancer6 trials
Show 3 more trials
Immunotherapy5 trials
Melanoma5 trials
Non-Small Cell Lung Cancer5 trials
Show 2 more trials
Colorectal Cancer5 trials
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
Unknown status·—·Phase 1·NCT06283303·8 enrolled
Renal Cell Carcinoma5 trials
Chemotherapy4 trials
Show 1 more trial
Head and Neck Squamous Cell Carcinoma4 trials
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06208826·268 enrolled
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT06647563·355 enrolled
Cervical Cancer4 trials
Toripalimab for High-risk Locally Advanced Cervical Cancer
Active, not recruiting·—·Phase 2·NCT06416696·57 enrolled
Show 1 more trial
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1/2·NCT06093438·20 enrolled
Locally Advanced4 trials
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT07246330·340 enrolled
Lung Cancer3 trials
Nab-paclitaxel3 trials
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
Unknown status·—·N/A·NCT04443036·44 enrolled
Urothelial Carcinoma3 trials
Gastric Cancer3 trials
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
Not yet recruiting·—·Phase 2·NCT06283121·30 enrolled
Lymphoma3 trials
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
Unknown status·—·Phase 2·NCT04338282·20 enrolled
Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma
Active, not recruiting·—·Phase 2·NCT06492629·43 enrolled
Conversion Therapy2 trials
Oral Squamous Cell Carcinoma2 trials
Metastatic Urothelial Cancer2 trials
Advanced Malignancies2 trials
Cholangiocarcinoma2 trials
Advanced Solid Tumours2 trials
Bladder Cancer2 trials
Advanced NSCLC2 trials
Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT04193098·10 enrolled
Solid Tumors2 trials
Pancreatic Cancer2 trials
Advanced Solid Malignancies1 trial
Efficacy and Safety1 trial
Chemoradiotherapy1 trial
Anti-PD-1 Antibody1 trial
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
Unknown status·—·Phase 2·NCT05461235·1 enrolled
Stereotactic Body Radiotherapy1 trial
Biliary Tract Cancer1 trial
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06717464·110 enrolled
Small Cell Carcinoma1 trial
Advanced Malignant Tumors1 trial
Metastasis1 trial
Undifferentiated Pleomorphic Sarcoma1 trial
Patients With Solid Tumors1 trial
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Recruiting·—·Phase 1/2·NCT06612632·100 enrolled
Resectable NSCLC1 trial
Liposarcoma1 trial
Targeted Therapy1 trial
Neoadjuvant Chemotherapy1 trial
Unresectable1 trial
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05493332·93 enrolled
Gastroesophageal Junction Adenocarcinoma1 trial
Malignant Pleural Mesothelioma1 trial
Other Solid Tumors1 trial
Brain Metastases1 trial
Cutaneous Melanoma1 trial
Refractory Metastatic1 trial
Induction Chemotherapy1 trial
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
Active, not recruiting·—·Phase 2·NCT05888402·50 enrolled
Locally-advanced Rectal Cancer1 trial
Neuroendocrine Carcinoma1 trial
Prospective1 trial
Hypopharyngeal Carcinoma1 trial
Hepatocarcinoma1 trial
Mucosal Melanoma1 trial
Renal insufficiency1 trial
Cervical Adenocarcinoma1 trial
Rectal Adenocarcinoma1 trial
Tracheal Squamous Cell Carcinoma1 trial
Papilloma1 trial
Advanced Malignant Solid Tumors1 trial
Locally Advanced Colon Cancer1 trial
Neoadjuvant Therapy1 trial
NSCLC1 trial
Locally Advanced Unresectable or Metastatic Solid Tumors1 trial
Esophageal Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Toripalimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Programmed Cell Death Protein 1 Antagonist[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- CCoherus Oncology, Inc.